Metabolically reprogrammed eosinophils impair T cell immunity and cause chronic skin infection
Eosinophils exhibit antimicrobial, cytotoxic and immunoregulatory effects, but our knowledge of their transcriptional and functional heterogeneity is still limited, especially in non-intestinal tissues. Here, we used a mouse model of chronic cutaneous inflammation elicited by the protozoan pathogen Leishmania mexicana to investigate the function and transcriptional dynamics of skin eosinophils. Infection of C57BL/6 mice triggered local and systemic eosinophilia that was driven by type 2 innate lymphoid cells and interleukin-5. Genetic and pharmacological eosinophil depletion led to an enhanced Th1 response, polarization towards M1-like macrophages and resolution of clinical disease, despite an unexpected simultaneous upregulation of IL-4. Single-cell transcriptomics revealed a skin-imprinted trajectory of inflammatory eosinophils that strongly expressed the glucose transporter Slc2a3 (GLUT3) These eosinophils impeded the function of Th1 cells by forming a competitive metabolic niche through preferential glucose uptake. Our findings uncover an inflammatory, metabolically reprogrammed eosinophil population that promotes chronic skin inflammation by limiting protective T cell responses.
Authors
- Stefan Wirtz (ORCID: https://orcid.org/0000-0001-6936-7431)
- David Barinberg (ORCID: https://orcid.org/0000-0003-4702-0749)
- Tobias Gold
- Ulrike Schleicher
- Alina Ulezko Antonova (ORCID: https://orcid.org/0000-0001-6772-0545)
- Baplu Rai (ORCID: https://orcid.org/0000-0001-7112-9272)
- D. Voehringer
- Heidi Sebald
- Jonathan Jantsch (ORCID: https://orcid.org/0000-0001-6944-2913)
- Christian Bogdan (ORCID: https://orcid.org/0000-0002-2300-0631)
- Dominik Lerm
- Marco Colonna
- Daniel Radtke
Institutions
- University of Cologne (DE)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Washington University in St. Louis (US)
- Universitätsklinikum Erlangen (DE)
- University Hospital Cologne (DE)
- Immunomedics (Germany) (DE)
Publication Details
- Journal
- EMBO Molecular Medicine
- Published
- 2026-03-11
- DOI
- https://doi.org/10.1038/s44321-026-00392-x
- Primary Topic
- IL-33, ST2, and ILC Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutsche Forschungsgemeinschaft
- Universitätsklinikum Erlangen